Lirum Therapeutics (Lirum Therapeutics) Current Accrued Expense : $1.38 Mil (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Current Accrued Expense?

Lirum Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2023 was $1.38 Mil.

Lirum Therapeutics's quarterly Current Accrued Expense declined from Dec. 2022 ($1.60 Mil) to Sep. 2023 ($1.28 Mil) but then increased from Sep. 2023 ($1.28 Mil) to Dec. 2023 ($1.38 Mil).

Lirum Therapeutics's annual Current Accrued Expense increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($1.60 Mil) but then declined from Dec. 2022 ($1.60 Mil) to Dec. 2023 ($1.38 Mil).

Lirum Therapeutics Current Accrued Expense Historical Data

The historical data trend for Lirum Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Current Accrued Expense Chart

Lirum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Current Accrued Expense

1.60

1.38

Lirum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Current Accrued Expense	-	-	1.60	1.28	1.38

Lirum Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Lirum Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

590 Madison Avenue, 21st Floor, New York, NY, USA, 10022

Website

https://www.lirumtx.com

Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines